Sars-cov-2 mrna (tozinameran-tris-sucrose) vaccine Side Effects

Applies to sars-cov-2 mrna (tozinameran-tris-sucrose) vaccine: intramuscular suspension.

Cardiovascular

Postmarketing reports: Myocarditis, pericarditis^[Ref]

Dermatologic

Uncommon (0.1% to 1%): Hyperhidrosis

Rare (0.01% to 0.1%): Night sweats

Postmarketing reports: Rash, Angioedema, pruritus, urticaria^[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (up to 10.7%)

Common (1% to 10%): Nausea

Postmarketing reports: Vomiting^[Ref]

Hematologic

Uncommon (0.1% to 1%): Lymphadenopathy^[Ref]

Hypersensitivity

Postmarketing reports: Severe allergic reactions (including anaphylaxis), other hypersensitivity reactions (e.g., rash, pruritus, urticaria, angioedema)^[Ref]

Local

Very common (10% or more): Injection site pain (up to 88.6%), injection site/localized swelling (up to 11.8%), injection site/localized redness (up to 10.4%)^[Ref]

Metabolic

Uncommon (0.1% to 1%): Decreased appetite^[Ref]

Musculoskeletal

Very common (10% or more): Muscle pain (up to 45.5%), new/worsened muscle pain (up to 39.3%), joint pain (up to 27.5%), new/worsened joint pain (up to 23.8%)

Postmarketing reports: Extremity (arm) pain^[Ref]

Nervous system

Very common (10% or more): Headache (up to 64.9%)

Uncommon (0.1% to 1%): Lethargy

Frequency not reported: Bell's palsy, facial paralysis, syncope^[Ref]

Other

Very common (10% or more): Fatigue (up to 70.1%), use of antipyretic or pain medication (up to 50.8%), chills (up to 41.5%), fever (up to 17.8%), fever of 38C or higher (up to 16.4%)

Uncommon (0.1% to 1%): Asthenia, malaise^[Ref]

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer